Dr. Chi on Abiraterone Versus Enzalutamide for Metastatic Castration-Resistant Prostate Cancer

Kim Chi, MD
Published: Monday, Jul 31, 2017



Kim Chi, MD, associate director of clinical research, Vancouver Prostate Centre, professor, Department of Medicine, University of British Columbia, discusses a study investigating abiraterone acetate (Zytiga) versus enzalutamide (Xtandi) for patients with metastatic castration-resistant prostate cancer (mCRPC).

There was a randomized phase II trial of abiraterone versus enzalutamide as first-line therapy for patients with mCRPC. This study demonstrated a significant difference, with enzalutamide experiencing a higher response rate then abiraterone; the prostate-specific antigen response rate was 77% versus 55%, respectively.



Kim Chi, MD, associate director of clinical research, Vancouver Prostate Centre, professor, Department of Medicine, University of British Columbia, discusses a study investigating abiraterone acetate (Zytiga) versus enzalutamide (Xtandi) for patients with metastatic castration-resistant prostate cancer (mCRPC).

There was a randomized phase II trial of abiraterone versus enzalutamide as first-line therapy for patients with mCRPC. This study demonstrated a significant difference, with enzalutamide experiencing a higher response rate then abiraterone; the prostate-specific antigen response rate was 77% versus 55%, respectively.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual International Congress of Oncology Pathology™: Towards Harmonization of Pathology and Oncology StandardsAug 30, 20182.0
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x